Inactivated influenza virus vaccines expressing COBRA hemagglutinin elicited broadly reactive, long-lived protective antibodies

References

• Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen C, Gran JM, Schanzer D, Cowling BJ. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–12. doi: 10.1016/S0140-6736(17)33293-2.
   PubMed Web of Science ®Google Scholar
• Vemula SV, Zhao J, Liu J, Wang X, Biswas S, Hewlett I. Current approaches for diagnosis of influenza virus infections in humans. Viruses. 2016;8(4):96. doi: 10.3390/v8040096.
   PubMed Web of Science ®Google Scholar
• Alymova IV, York IA, Air GM, Cipollo JF, Gulati S, Baranovich T, Kumar A, Zeng H, Gansebom S, McCullers JA. Glycosylation changes in the globular head of H3N2 influenza hemagglutinin modulate receptor binding without affecting virus virulence. Sci Rep. 2016;6(1):1–15. doi: 10.1038/srep36216.
   PubMedGoogle Scholar
• Stöhr K, Bucher D, Colgate T, Wood J, Le J, Manojkumar R, Pokorny BA, Silverman J, Bucher D, Wood JM. Influenza virus surveillance, vaccine strain selection, and manufacture. In: Kawaoka Y, Neumann G, editors. Influenza virus: methods and protocols. New York, NY, USA: Springer; 2012. p. 147–62.
   Google Scholar
• Barberis I, Myles P, Ault S, Bragazzi N, Martini M. History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines. J Prev Med Hyg. 2016;57(3):E115.
   PubMedGoogle Scholar
• Huang X, Fan T, Li L, Nian X, Zhang J, Gao X, Zhao W, Chen W, Zhang Z, Yao Z. Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3–60 years: a phase III randomized clinical noninferiority trial. Hum Vaccines Immunother. 2022;18(5):2079924. doi: 10.1080/21645515.2022.2079924.
   PubMed Web of Science ®Google Scholar
• Lewnard JA, Cobey S. Immune history and influenza vaccine effectiveness. NATO Adv Sci Inst Se. 2018;6(2):28. doi: 10.3390/vaccines6020028.
   Google Scholar
• Weir JP, Gruber MF. An overview of the regulation of influenza vaccines in the United States. Influenza Other Respi Viruses. 2016;10(5):354–60. doi: 10.1111/irv.12383.
   PubMed Web of Science ®Google Scholar
• Erbelding EJ, Post DJ, Stemmy EJ, Roberts PC, Augustine AD, Ferguson S, Paules CI, Graham BS, Fauci AS. A universal influenza vaccine: the strategic plan for the national institute of allergy and infectious diseases. J Infect Dis. 2018;218(3):347–54. doi: 10.1093/infdis/jiy103.
   PubMed Web of Science ®Google Scholar
• Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem. 2000;69(1):531–69. doi: 10.1146/annurev.biochem.69.1.531.
   PubMed Web of Science ®Google Scholar
• Giles BM, Ross TM. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine. 2011;29(16):3043–54. doi: 10.1016/j.vaccine.2011.01.100.
   PubMed Web of Science ®Google Scholar
• Allen JD, Ross TM, Subbarao K. Bivalent H1 and H3 COBRA recombinant hemagglutinin vaccines elicit seroprotective antibodies against H1N1 and H3N2 influenza viruses from 2009 to 2019. J Virol. 2022;96(7):e01652–01621. doi: 10.1128/jvi.01652-21.
   PubMed Web of Science ®Google Scholar
• Carter DM, Darby CA, Lefoley BC, Crevar CJ, Alefantis T, Oomen R, Anderson SF, Strugnell T, Cortés-Garcia G, Vogel TU, et al. Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses. J Virol. 2016;90(9):4720–34. doi: 10.1128/JVI.03152-15.
   PubMed Web of Science ®Google Scholar
• Giles BM, Crevar CJ, Carter DM, Bissel SJ, Schultz-Cherry S, Wiley CA, Ross TM. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis. 2012;205(10):1562–70. doi: 10.1093/infdis/jis232.
   PubMed Web of Science ®Google Scholar
• Huang Y, França MS, Allen JD, Shi H, Ross TM. Next generation of computationally optimized broadly reactive HA vaccines elicited cross-reactive immune responses and provided protection against H1N1 virus infection. NATO Adv Sci Inst Se. 2021;9(7):793. doi: 10.3390/vaccines9070793.
   Google Scholar
• Wong TM, Allen JD, Bebin-Blackwell A-G, Carter DM, Alefantis T, DiNapoli J, Kleanthous H, Ross TM, Schultz-Cherry S. Computationally optimized broadly reactive hemagglutinin elicits hemagglutination inhibition antibodies against a panel of H3N2 influenza virus cocirculating variants. J Virol. 2017;91(24):e01581–01517. doi: 10.1128/JVI.01581-17.
   PubMed Web of Science ®Google Scholar
• Nachbagauer R, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, Berlanda-Scorza F, Stadlbauer D, Wilson PC, Aydillo T, et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med. 2021;27(1):106–14. doi: 10.1038/s41591-020-1118-7.
   PubMed Web of Science ®Google Scholar
• Skarlupka AL, Ross TM. Immune imprinting in the influenza ferret model. NATO Adv Sci Inst Se. 2020;8(2):173. doi: 10.3390/vaccines8020173.
   Google Scholar
• Vatti A, Monsalve DM, Pacheco Y, Chang C, Anaya J-M, Gershwin ME. Original antigenic sin: a comprehensive review. J Autoimmun. 2017;83:12–21. doi: 10.1016/j.jaut.2017.04.008.
   PubMed Web of Science ®Google Scholar
• Zhou B, Meliopoulos VA, Wang W, Lin X, Stucker KM, Halpin RA, Stockwell TB, Schultz-Cherry S, Wentworth DE, Dermody TS. Reversion of cold-adapted live attenuated influenza vaccine into a pathogenic virus. J Virol. 2016;90(19):8454–63. doi: 10.1128/JVI.00163-16.
   PubMed Web of Science ®Google Scholar
• Eisfeld AJ, Neumann G, Kawaoka Y. Influenza a virus isolation, culture and identification. Nat Protoc. 2014;9(11):2663–81. doi: 10.1038/nprot.2014.180.
   PubMed Web of Science ®Google Scholar
• Pica N, Iyer A, Ramos I, Bouvier NM, Fernandez-Sesma A, García-Sastre A, Lowen AC, Palese P, Steel J. The DBA.2 mouse is susceptible to disease following infection with a broad, but limited, range of influenza a and B viruses. J Virol. 2011;85(23):12825–9. doi: 10.1128/jvi.05930-11.
   PubMed Web of Science ®Google Scholar
• Use CFMPFH. Guideline on influenza vaccines—non-clinical and clinical module. Eur Med Agency EMA/CHMP/VWP/457259/2014. 2016;44:1–31.
   Google Scholar
• Allen JD, Ross TM. Next generation methodology for updating HA vaccines against emerging human seasonal influenza a (H3N2) viruses. Sci Rep. 2021;11(1):4554. doi: 10.1038/s41598-020-79590-7.
   PubMed Web of Science ®Google Scholar
• Allen JD, Ray S, Ross TM, Kang S-M. Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses. PLOS ONE. 2018;13(9):e0204284. doi: 10.1371/journal.pone.0204284.
   PubMed Web of Science ®Google Scholar
• Allen JD, Ross TM. H3N2 influenza viruses in humans: Viral mechanisms, evolution, and evaluation. Hum Vaccines Immunother. 2018;14(8):1840–7. doi: 10.1080/21645515.2018.1462639.
   PubMed Web of Science ®Google Scholar
• Carter DM, Darby CA, Johnson SK, Carlock MA, Kirchenbaum GA, Allen JD, Vogel TU, Delagrave S, DiNapoli J, Kleanthous H, et al. Elicitation of protective antibodies against a broad panel of H1N1 viruses in ferrets preimmune to historical H1N1 influenza viruses. J Virol. 2017;91(24):e01283–01217. doi: 10.1128/JVI.01283-17.
   PubMed Web of Science ®Google Scholar
• Ross TM, Gokanapudi N, Ge P, Shi H, Richardson RA, Pierce SR, Sanchez P, Ullah S, De Luca E, Sautto GA, et al. Kinetic of the antibody response following AddaVax-adjuvanted immunization with recombinant influenza antigens. Vaccines. 2022;10:1315.
   Web of Science ®Google Scholar
• Firacative C, Gressler AE, Schubert K, Schulze B, Müller U, Brombacher F, von Bergen M, Alber G. Identification of T helper (Th)1- and Th2-associated antigens of Cryptococcus neoformans in a murine model of pulmonary infection. Sci Rep. 2018;8(1):2681. doi: 10.1038/s41598-018-21039-z.
   PubMedGoogle Scholar
• Gouma S, Weirick M, Hensley SE. Antigenic assessment of the H3N2 component of the 2019–2020 Northern Hemisphere influenza vaccine. Nat Commun. 2020;11(1):2445. doi: 10.1038/s41467-020-16183-y.
   PubMed Web of Science ®Google Scholar
• Bangaru S, Zhang H, Gilchuk IM, Voss TG, Irving RP, Gilchuk P, Matta P, Zhu X, Lang S, Nieusma T. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nat Commun. 2018;9(1):2669. doi: 10.1038/s41467-018-04704-9.
   PubMed Web of Science ®Google Scholar
• Pulendran B, Arunachalam S, P. & O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20(6):454–75. doi: 10.1038/s41573-021-00163-y.
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801. doi: 10.1016/j.cell.2006.02.015.
   PubMed Web of Science ®Google Scholar
• Gardner EM, Beli E, Clinthorne JF, Duriancik DM. Energy intake and response to infection with influenza. Annu Rev Nutr. 2011;31(1):353–67. doi: 10.1146/annurev-nutr-081810-160812.
   PubMedGoogle Scholar
• Kim JH, Skountzou I, Compans R, Jacob J. Original antigenic sin responses to influenza viruses. J Immunol. 2009;183(5):3294–301. doi: 10.4049/jimmunol.0900398.
   PubMed Web of Science ®Google Scholar
• Krammer F. The human antibody response to influenza a virus infection and vaccination. Nat Rev Immunol. 2019;19(6):383–97. doi: 10.1038/s41577-019-0143-6.
   PubMed Web of Science ®Google Scholar
• Nachbagauer R, Choi A, Hirsh A, Margine I, Iida S, Barrera A, Ferres M, Albrecht RA, García-Sastre A, Bouvier NM. Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nat Immunol. 2017;18(4):464–73. doi: 10.1038/ni.3684.
   PubMed Web of Science ®Google Scholar
• Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol. 2015;15(3):149–59. doi: 10.1038/nri3802.
   PubMed Web of Science ®Google Scholar
• Nian X, Zhang J, Deng T, Liu J, Gong Z, Lv C, Yao L, Li J, Huang S, Yang X. Addavax formulated with PolyI: C as a potential adjuvant of MDCK-based influenza vaccine enhances local, cellular, and antibody protective immune response in mice. Aaps Pharm Sci Tech. 2021;22(8):270. doi: 10.1208/s12249-021-02145-0.
   PubMed Web of Science ®Google Scholar
• Hovden AO, Cox R, Haaheim L. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand J Immunol. 2005;62(1):36–44. doi: 10.1111/j.1365-3083.2005.01633.x.
   PubMed Web of Science ®Google Scholar
• Jegaskanda S, Reading PC, Kent SJ. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine. J Immunol. 2014;193(2):469–75. doi: 10.4049/jimmunol.1400432.
   PubMed Web of Science ®Google Scholar
• Heui Seo S, Hoffmann E, Webster RG. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med. 2002;8(9):950–4. doi: 10.1038/nm757.
   PubMed Web of Science ®Google Scholar
• Soghoian DZ, Streeck H. Cytolytic CD4+ T cells in viral immunity. Expert Rev Vaccines. 2010;9(12):1453–63. doi: 10.1586/erv.10.132.
   PubMed Web of Science ®Google Scholar
• Hay AJ, Gregory V, Douglas AR, Lin YP. The evolution of human influenza viruses. Phil Trans R Soc Lond B. 2001;356(1416):1861. doi: 10.1098/rstb.2001.0999.
   PubMed Web of Science ®Google Scholar